Enantioselectivity in the methylation of the catecholic phase I metabolites of methylenedioxy designer drugs and their capability to inhibit catechol-O-methyltransferase-catalyzed dopamine 3-methylation.

@article{Meyer2009EnantioselectivityIT,
  title={Enantioselectivity in the methylation of the catecholic phase I metabolites of methylenedioxy designer drugs and their capability to inhibit catechol-O-methyltransferase-catalyzed dopamine 3-methylation.},
  author={Markus R Meyer and Hans H Maurer},
  journal={Chemical research in toxicology},
  year={2009},
  volume={22 6},
  pages={
          1205-11
        }
}
The designer drugs R,S-3,4-methylenedioxy-methamphetamine (MDMA, Ecstasy), R,S-3,4-methylenedioxy-ethylamphetamine (MDEA, Eve), and R,S-N-methyl-benzodioxolyl-butanamine (MBDB, Eden) are chiral compounds, and their in vitro and in vivo metabolism is enantioselective with a preference for the S-enantiomer caused in part by P450-mediated demethylenation. As the elimination of the catecholamine metabolites could also be enantioselective, the aim of the present study was to investigate the O… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-8 of 8 citations

References

Publications referenced by this paper.
Showing 1-10 of 49 references

Human pharmacology

  • M. Segura, J. Segura, J. Cami
  • 2004